Search
Di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone
go.drugbank.com/drugs/DB15235InvestigationalDi-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone is under investigation in clinical trial NCT02688101 (Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced
Synonyms: Di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazoneMolybdenum cofactor
go.drugbank.com/drugs/DB02137ExperimentalAbsence of molybdenum cofactor leads to accumulation of toxic levels of sulphite and neurological damage usually leading to death within months of birth, due to the lack of active sulfite oxidase.
Valoctocogene roxaparvovec
go.drugbank.com/drugs/DB15561ApprovedInvestigationalWithdrawn[L43292] Hemophilia A treatments such as prophylactic regimens of exogenous factor VIII or [emicizumab] improve the clinical outcomes of patients but do not eliminate breakthrough bleeding. … [L43282] The expression of hFVIII-SQ is driven by a liver-specific promoter, which enables hepatocytes to produce factor VIII protein and increase the levels of active factor VIII in blood.
Calfactant
go.drugbank.com/drugs/DB06415ApprovedInvestigationalCalfactant is a sterile, non-pyrogenic lung surfactant intended for intratracheal instillation. … Calfactant has been shown to decrease the incidence of respiratory distress syndrome, mortality due to respiratory distress syndrome, and air leaks associated with respiratory distress syndrome in clinical
Levomefolic acid
go.drugbank.com/drugs/DB11256ApprovedSupplementation of levomefolic acid is desired over folic acid due to reduced potential for masking vitamin B12 deficiency symptoms. … Levomefolate is approved as a food additive and is designated a GRAS (generally regarded as safe) compound [L773].
Mixtures: L-Methyl-B6-B12, L-Methyl MCSynonyms: L-5-MTHF, L-methylfolateZYC300
go.drugbank.com/drugs/DB04986InvestigationalZYC300 is a plasmid DNA of CYP1B1 encapsulated in biodegradable poly-DL-lactide-coglycolide microparticles. … It is designed as a vaccine, intended to increase immune system sensitivity to CYP1B1, an enzyme highly prevalent in tumor cells.
Lexacalcitol
go.drugbank.com/drugs/DB03451ExperimentalLexacalcitol is a solid. This compound belongs to the vitamin D and derivatives class of chemicals. These are compounds containing a secosteroid backbone, usually secoergostane or secocholestane. … It is known to target the vitamin D3 receptor.
Categories: Vitamin D and AnaloguesGaradacimab
go.drugbank.com/drugs/DB15629Approved[L53283,A273998] Garadacimab received its first approval in Australia and the UK in January 2025, and has since been approved in a number of other jurisdictions, including the EU and Japan. … Garadacimab is a fully human monoclonal antibody targeted against activated factor XII.
Rotigotine
go.drugbank.com/drugs/DB05271ApprovedInvestigationalHowever, all Neupro patches in the United States and some of Europe were recalled in 2008 due to delivery mechanism issues. Rotigotine has been authorized as a treatment for RLS since August 2008. … It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours.
iCo-007
go.drugbank.com/drugs/DB05268Investigational) such as age-related macular degeneration (AMD) and diabetic retinopathy(DR). … iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis